Oracle
ORCL
Vale SA
VALE
Toll Brothers
TOL
4
D.R. Horton
DHI
5
Lennar Corp
LEN
US Stock MarketDetailed Quotes
BCAB BioAtla
- 0.4449
- +0.0043+0.98%
Close Apr 28 16:00 ET
25.98MMarket Cap-0.31P/E (TTM)
0.4535High0.4301Low417.37KVolume0.4405Open0.4406Pre Close183.99KTurnover0.99%Turnover RatioLossP/E (Static)58.40MShares3.420052wk High1.82P/B18.82MFloat Cap0.240052wk Low--Dividend TTM42.30MShs Float76.6300Historical High--Div YieldTTM5.31%Amplitude0.2400Historical Low0.4400Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
BioAtla Stock Forum
BioAtla's Breakthrough: 66% Survival Rate in Lung Cancer Trial Amid Strategic Cost Reductions
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
Monday, 16th December at 8:00 am
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treat...
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown ...
No comment yet